CSTL CASTLE BIOSCIENCES INC

NEUTRAL Impact: 4/10 144
Horizon days Filed Jun 1, 2026 Processed 5d ago SEC 0001958244-26-000337
Form 144 — notice of proposed sale of securities

Price Chart

Loading chart...

Executive Summary

CEO Derek Maetzold filed a Form 144 on June 1, 2026, to sell 14,008 shares of Castle Biosciences common stock, with an estimated aggregate market value of approximately $293,748. The sale is part of a Rule 10b5-1 trading plan adopted on December 3, 2025, covering shares held by Maetzold and related family trusts. While the CEO's intent to sell is notable, the plan was established six months ago, reducing the timing signal.

Actionable Insight

The CEO's 10b5-1 plan was adopted six months ago, so the filing does not signal a near-term negative catalyst. However, the absence of insider buying and the ongoing plan sales warrant monitoring for any change in the company's operational trajectory or upcoming earnings. The sale is small relative to market cap and likely part of routine portfolio diversification.

Key Facts

  • CEO Derek Maetzold intends to sell 14,008 shares via Form 144.
  • Estimated aggregate market value of the proposed sale is approximately $293,748.
  • Sale is under a Rule 10b5-1 trading plan dated December 3, 2025.
  • Shares are being sold through Goldman Sachs & Co. LLC.
  • The plan covers shares from Maetzold directly and multiple family trusts.
  • Company market cap is approximately $639 million; the sale represents ~0.05% of market cap.
  • No recent insider buying activity was reported in the prior 30 days.

Financial Impact

Proposed sale of ~$294K worth of CSTL common stock, representing about 0.05% of the company's $639M market cap.

dilutioninsider ownership

Risk Factors

  • CEO selling under a pre-arranged plan may still be perceived negatively by the market if sentiment is fragile.
  • Continued insider selling without buying could signal lack of confidence in near-term prospects.
  • The 10b5-1 plan does not preclude additional unplanned sales, which would be more concerning.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
93% bullish (14 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001958244-26-000337
Document: 0001958244-26-000337-index.html0001958244-26-000337
Document: 0001958244-26-000337.txt0001958244-26-000337
10 reports for CSTL
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +24.87%Mar 5, 2026
Filters
Rows
Reports for CSTL — sortable, filterable
Type Now
Jun 1, 2026
5d ago
144
NEUTRAL ★ 4/10
awaiting T+5
May 7, 2026
4w ago
144
NEUTRAL ★ 3/10
$19.83 $18.88▼ −4.79%▼ −6.25%$21.01 (+5.95%)
Apr 8, 2026
8w ago
DEFA14A
NEUTRAL ★ 3/10
$25.19 $24.62▼ −2.26%▼ −5.78%$21.01 (−16.59%)
Mar 13, 2026
12w ago
Press Release
BULLISH ★ 7/10
$25.56 $25.00▼ −2.19%▼ −0.07%$21.01 (−17.80%)
Mar 12, 2026
12w ago
Insider Cluster
BEARISH ★ 6/10
$25.32 $25.70▼ −1.50%▼ −2.48%$21.01 (+17.02%)
Mar 12, 2026
12w ago
Insider Cluster
BEARISH ★ 7/10
$25.32 $25.70▼ −1.50%▼ −2.48%$21.01 (+17.02%)
Mar 9, 2026
12w ago
Press Release
BULLISH ★ 7/10
$27.02 $25.83▼ −4.40%▼ −3.05%$21.01 (−22.24%)
Mar 5, 2026
13w ago
Insider Cluster
BEARISH ★ 7/10
$27.91 $25.32▲ +9.28%▲ +7.04%$21.01 (+24.72%)
Mar 5, 2026
13w ago
Insider Cluster
BEARISH ★ 5/10
$27.91 $25.32▲ +9.28%▲ +7.04%$21.01 (+24.72%)
Mar 3, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.57 $26.60▼ −3.52%▼ −3.04%$21.01 (−23.79%)
Showing 10 of 10

US Market Status

Market Closed — Opens Mon (14h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access